Trial · NCT03710057
Effect of Ivabradine in Lowering Heart Rate and Quality of Life in Chronic Heart Failure Patients
NCT03710057, Completed, Getz Pharma
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effect of Ivabradine in Lowering Heart Rate and Quality of Life in Chronic Heart Failure Patients. Trials, record NCT03710057. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03710057
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect of Ivabradine in Lowering Heart Rate and Quality of Life in Chronic Heart Failure Patients
- NCT number
- NCT03710057
- Status
- Completed
- Enrollment
- 50 participants, actual
- Lead sponsor
- Getz Pharma
- Conditions
- Chronic Heart Failure
- Interventions
- Ivabradine
- First posted
- 2018-10-17
- Last updated
- 2018-10-17
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mean difference of Heart Rate | at 4 week and 8 week | The primary end-point was the overall response rate of patients to Ivabradine in achieving HR \<70 Bpm |
| Secondary | Percentage of problems reported in EQ-5D descriptive system | at 4 week and 8 week | Quality of Life was determined through validated questionnaire EQ-5D-3L. It also assesses five dimensions of HR quality of life (HRQoL): mobility, self-care, usual activities, pain or discomfort, and anxiety or depression. Each dimension is measured one to three levels i.e 1, 2, 3. Where level 2 \& 3 indicates 'problem' and level 1 denotes to 'no problem'. |
| Secondary | Median score of EQ-5D visual analogue scale | at 4 week and 8 week | The EQ-5D registers the self-rated health status of the respondent on the vertically visual analogue scale (EQ-5D VAS) from 0 to 100 where 100 indicates 'Best imaginable health' and 0 is said to be a 'Worst imagine health state'. |
| Other | Percentage of Reported Adverse Drug Reactions | upto 8 weeks | The pre-defined secondary outcome was to determine Safety and tolerability by monitoring adverse drug reactions. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03710057
GET https://conductscience.org/api/trials/v1/NCT03710057/registered